These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32866170)

  • 1. Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses.
    Chauffour A; Robert J; Veziris N; Aubry A; Pethe K; Jarlier V
    PLoS Negl Trop Dis; 2020 Aug; 14(8):e0007857. PubMed ID: 32866170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
    Converse PJ; Almeida DV; Tyagi S; Xu J; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice.
    Chauffour A; Robert J; Veziris N; Aubry A; Jarlier V
    PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005066. PubMed ID: 27755552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer.
    Almeida DV; Omansen TF; Li SY; Lee J; Grosset JH; Converse PJ; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model.
    Almeida DV; Converse PJ; Omansen TF; Tyagi S; Tasneen R; Kim J; Nuermberger EL
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32205344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Dose, Duration, and Immune Status on Efficacy of Ultrashort Telacebec Regimens in Mouse Models of Buruli Ulcer.
    Komm O; Almeida DV; Converse PJ; Omansen TF; Nuermberger EL
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0141821. PubMed ID: 34460302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.
    Omansen TF; Almeida D; Converse PJ; Li SY; Lee J; Stienstra Y; van der Werf T; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the Mycobacterium ulcerans cytochrome bc
    Scherr N; Bieri R; Thomas SS; Chauffour A; Kalia NP; Schneide P; Ruf MT; Lamelas A; Manimekalai MSS; Grüber G; Ishii N; Suzuki K; Tanner M; Moraski GC; Miller MJ; Witschel M; Jarlier V; Pluschke G; Pethe K
    Nat Commun; 2018 Dec; 9(1):5370. PubMed ID: 30560872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice.
    Almeida D; Converse PJ; Ahmad Z; Dooley KE; Nuermberger EL; Grosset JH
    PLoS Negl Trop Dis; 2011 Jan; 5(1):e933. PubMed ID: 21245920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease.
    Almeida DV; Converse PJ; Li SY; Tyagi S; Nuermberger EL; Grosset JH
    PLoS Negl Trop Dis; 2013; 7(2):e2085. PubMed ID: 23469308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice.
    Ji B; Chauffour A; Robert J; Jarlier V
    Antimicrob Agents Chemother; 2008 Jun; 52(6):1912-6. PubMed ID: 18391038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repurposing of Tuberculosis Drug Candidates for the Treatment of Mycobacterium ulcerans Disease.
    Warryn L; Pluschke G
    Chimia (Aarau); 2023 Sep; 77(9):577-581. PubMed ID: 38047833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward a Single-Dose Cure for Buruli Ulcer.
    Thomas SS; Kalia NP; Ruf MT; Pluschke G; Pethe K
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice.
    Dega H; Bentoucha A; Robert J; Jarlier V; Grosset J
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3193-6. PubMed ID: 12234844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
    Ji B; Lefrançois S; Robert J; Chauffour A; Truffot C; Jarlier V
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1921-6. PubMed ID: 16723546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impacts of dosing frequency of the combination rifampin-streptomycin on its bactericidal and sterilizing activities against Mycobacterium ulcerans in mice.
    Ji B; Chauffour A; Aubry A; Robert J; Ibrahim M; Jarlier V
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2955-9. PubMed ID: 19364857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infection.
    Zhang T; Li SY; Converse PJ; Grosset JH; Nuermberger EL
    PLoS Negl Trop Dis; 2013; 7(12):e2598. PubMed ID: 24367713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection.
    Zhang T; Li SY; Converse PJ; Almeida DV; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2011 Jan; 55(1):56-61. PubMed ID: 21078940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.
    Ruf MT; Schütte D; Chauffour A; Jarlier V; Ji B; Pluschke G
    Antimicrob Agents Chemother; 2012 Feb; 56(2):687-96. PubMed ID: 22143518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telacebec (Q203), a New Antituberculosis Agent.
    de Jager VR; Dawson R; van Niekerk C; Hutchings J; Kim J; Vanker N; van der Merwe L; Choi J; Nam K; Diacon AH
    N Engl J Med; 2020 Mar; 382(13):1280-1281. PubMed ID: 32212527
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.